iBio (IBIO) Projected to Announce Earnings on Wednesday

Key Points

• iBio is expected to report Q1 fiscal 2027 results before the market opens on November 11, with analysts forecasting a loss of $0.07 per share and revenue of $0.03 million. The earnings call is scheduled for November 13.
• In its latest reported quarter, iBio posted a loss of $0.04 per share, beating the consensus estimate of a $0.07 loss. Analysts expect losses of $0.39 per share for the current fiscal year and $0.60 for the next.
• Analyst views are mixed: MarketBeat lists a consensus “Buy” rating and $6.00 price target, while recent ratings include both “Sell” calls and a “Buy” rating with a $7.00 target.

iBio (NASDAQ:IBIO - Get Free Report) is anticipated to release its Q1 2027 results before the market opens on Wednesday, November 11th. Analysts expect iBio to announce earnings of ($0.07) per share and revenue of $0.03 million for the quarter. Investors are encouraged to explore the company's upcoming Q1 2027 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

iBio (NASDAQ:IBIO - Get Free Report) last released its quarterly earnings results on Friday, August 28th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.03. On average, analysts expect iBio to post ($0.39) EPS for the current fiscal year and ($0.60) EPS for the next fiscal year.

iBio Trading Up 0.7%

iBio stock traded up $0.01 during trading on Wednesday, hitting $0.83. The company had a trading volume of 29,780 shares, compared to its average volume of 1,083,023. iBio has a 1-year low of $0.69 and a 1-year high of $3.82. The company's 50 day simple moving average is $1.07 and its 200-day simple moving average is $1.69. The stock has a market cap of $53.31 million, a price-to-earnings ratio of -2.44 and a beta of 1.48.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on IBIO shares. Wall Street Zen downgraded iBio from a "hold" rating to a "sell" rating in a research note on Sunday, September 13th. HC Wainwright started coverage on iBio in a research report on Thursday, September 17th. They issued a "buy" rating and a $7.00 price objective on the stock. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of iBio in a report on Monday, September 21st. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $6.00.

About iBio

iBio, Inc NASDAQ: IBIO is a biotechnology company focused on discovering and developing next-generation antibody therapeutics. The company uses artificial intelligence, machine learning and computational biology to identify and optimize antibody candidates for potential use in cancer and other serious diseases.

iBio's discovery capabilities are built around proprietary antibody-design and profiling technologies, including platforms intended to improve the speed and quality of therapeutic antibody development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.